Advanced search
1 file | 1.07 MB

Angiogenesis in chronic liver disease and its complications

(2011) LIVER INTERNATIONAL. 31(2). p.146-162
Author
Organization
Abstract
Nowadays, liver cancer, cirrhosis and other liver-related diseases are the fifth most common cause of mortality in the UK. Furthermore, chronic liver diseases (CLDs) are one of the major causes of death, which are still increasing year-on-year. Therefore, knowledge about the pathophysiology of CLDs and its complications is of uttermost importance. The goal of this review is to clarify the role of angiogenesis in the disease progression of various liver diseases. Looking closer at the pathophysiology of portal hypertension (PH), fibrosis, cirrhosis, non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), we find that angiogenesis is a recurring factor in the disease progression. In PH, several factors involved in its pathogenesis, such as hypoxia, oxidative stress, inflammation and shear stress are potential mediators for the angiogenic response. The progression from fibrosis to cirrhosis, the end-point of CLDs, is distinguished by a prolonged inflammatory and fibrogenic process that leads to an abnormal angioarchitecture distinctive for cirrhosis. In several stages of NASH, a link might be made between the disease progression and hepatic microvasculature changes. HCC is one of the most vascular solid tumours in which angiogenesis plays an important role in its development, progression and metastasis. The close relationship between the progression of CLDs and angiogenesis emphasises the need for anti-angiogenic therapy as a tool for blocking or slowing down the disease progression. The fact that angiogenesis plays a pivotal role in CLDs gives rise to new opportunities for treating CLDs and its complications.
Keywords
chronic liver diseases, non-alcoholic steatohepatitis, hepatocellular carcinoma, angiogenesis, portal hypertension, ENDOTHELIAL-GROWTH-FACTOR, ADVANCED HEPATOCELLULAR-CARCINOMA, TYROSINE KINASE INHIBITOR, HEPATIC STELLATE CELLS, PHASE-II TRIAL, HYPERDYNAMIC SPLANCHNIC CIRCULATION, PORTAL HYPERTENSIVE-RATS, HYPOXIA-INDUCIBLE FACTOR, NONALCOHOLIC STEATOHEPATITIS, FACTOR RECEPTOR

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.07 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Coulon, Stephanie, Femke Heindryckx, Anja Geerts, Christophe Van Steenkiste, Isabelle Colle, and Hans Van Vlierberghe. 2011. “Angiogenesis in Chronic Liver Disease and Its Complications.” Liver International 31 (2): 146–162.
APA
Coulon, S., Heindryckx, F., Geerts, A., Van Steenkiste, C., Colle, I., & Van Vlierberghe, H. (2011). Angiogenesis in chronic liver disease and its complications. LIVER INTERNATIONAL, 31(2), 146–162.
Vancouver
1.
Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. LIVER INTERNATIONAL. 2011;31(2):146–62.
MLA
Coulon, Stephanie, Femke Heindryckx, Anja Geerts, et al. “Angiogenesis in Chronic Liver Disease and Its Complications.” LIVER INTERNATIONAL 31.2 (2011): 146–162. Print.
@article{1123620,
  abstract     = {Nowadays, liver cancer, cirrhosis and other liver-related diseases are the fifth most common cause of mortality in the UK. Furthermore, chronic liver diseases (CLDs) are one of the major causes of death, which are still increasing year-on-year. Therefore, knowledge about the pathophysiology of CLDs and its complications is of uttermost importance. The goal of this review is to clarify the role of angiogenesis in the disease progression of various liver diseases. Looking closer at the pathophysiology of portal hypertension (PH), fibrosis, cirrhosis, non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), we find that angiogenesis is a recurring factor in the disease progression. In PH, several factors involved in its pathogenesis, such as hypoxia, oxidative stress, inflammation and shear stress are potential mediators for the angiogenic response. The progression from fibrosis to cirrhosis, the end-point of CLDs, is distinguished by a prolonged inflammatory and fibrogenic process that leads to an abnormal angioarchitecture distinctive for cirrhosis. In several stages of NASH, a link might be made between the disease progression and hepatic microvasculature changes. HCC is one of the most vascular solid tumours in which angiogenesis plays an important role in its development, progression and metastasis. The close relationship between the progression of CLDs and angiogenesis emphasises the need for anti-angiogenic therapy as a tool for blocking or slowing down the disease progression. The fact that angiogenesis plays a pivotal role in CLDs gives rise to new opportunities for treating CLDs and its complications.},
  author       = {Coulon, Stephanie and Heindryckx, Femke and Geerts, Anja and Van Steenkiste, Christophe and Colle, Isabelle and Van Vlierberghe, Hans},
  issn         = {1478-3223},
  journal      = {LIVER INTERNATIONAL},
  language     = {eng},
  number       = {2},
  pages        = {146--162},
  title        = {Angiogenesis in chronic liver disease and its complications},
  url          = {http://dx.doi.org/10.1111/j.1478-3231.2010.02369.x},
  volume       = {31},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: